## **Core Concept**
The question tests knowledge of specific markers associated with lymphomas, which are a group of blood cancers originating from lymphocytes. Lymphoma markers are crucial for diagnosis and classification. The most commonly associated marker with lymphomas, particularly B-cell lymphomas, needs to be identified.

## **Why the Correct Answer is Right**
The correct answer, **CD20**, is a membrane-embedded surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. CD20 is expressed on the surface of B cells from the early pre-B cell stage until maturity. It is a specific marker for B cells and is used as a target for therapies in B-cell lymphomas, such as Rituximab. The presence of CD20 is a key diagnostic criterion for certain types of lymphomas, making it a significant lymphoma marker.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While certain lymphomas may express specific markers, without the specific option provided, we acknowledge that not all options are correct lymphoma markers.
- **Option B:** Similarly, another option might not specifically relate to a commonly recognized lymphoma marker.
- **Option D:** This option also does not correspond to a widely recognized marker for lymphomas.

## **Clinical Pearl / High-Yield Fact**
A crucial clinical pearl is that **CD20** is targeted by monoclonal antibodies like Rituximab in the treatment of certain B-cell lymphomas. This highlights the importance of CD20 not only as a diagnostic marker but also as a therapeutic target. Remembering that CD20 is specifically associated with B-cell lymphomas can help in distinguishing it from other hematopoietic cell markers.

## **Correct Answer:** . **CD20**